Objective: To evaluate the effects of sitagliptin, a DPP-4 inhibitor, on bone remodeling using dynamic histomorphometry and assess DPP4 gene expression in bone tissue of ovariectomized (OVX) rats, a model of hypoestrogenism. Method: Non-diabetic female Wistar rats were divided into five groups: OVX-S (ovariectomized, sitagliptin-treated, n=9), OVX (ovariectomized, saline-treated, n=7), SHAM-S (sham-operated, sitagliptin-treated, n=10), SHAM (sham-operated, saline-treated, n=7), and control (n=7). Sitagliptin (25 mg/kg) or saline was administered daily via gavage for 13 weeks post-surgery. Bone histomorphometry of the right tibia assessed structural (BV/TV, Tb.Th, Tb.Sp, Tb.N), remodeling static (OS/BS, O.Th, ES/BS) and dynamic (MS/BS, MAR, BFR/BS) parameters. DPP4 gene expression in the right femur was analyzed using RT-qPCR. Statistical analyses included ANCOVA and Kruskal-Wallis tests (p<0.05). Results: Sitagliptin mitigated bone resorption in OVX-S compared to OVX. Structural parameters showed lower BV/TV and Tb.N, and higher Tb.Sp in OVX and OVX-S versus SHAM, SHAM-S, and control, with OVX-S having smaller Tb.Sp than OVX (p=0.012). Static parameters indicated higher OS/BS in OVX-S versus SHAM-S (p<0.04). Dynamic parameters revealed that the ovariectomized (OVX) group demonstrated greater number of fluorescent labels and therefore a higher mineralized surface (MS/BS) than the OVX-S (p<0.01), indicative that sitagliptin effectively mitigated increased bone resorption associated with hypoestrogenism. Dynamic parameters also revealed greater BFR/BS in OVX compared to all groups (p<0.001). DPP4 expression was significantly lower in OVX-S and SHAM-S versus OVX (p<0.01). Conclusion: Sitagliptin reduces bone remodeling in hypoestrogenic states, likely by decreasing resorption, as shown by histomorphometry and reduced DPP4 expression, suggesting its potential to prevent bone loss in conditions like menopause.